Eledon Pharmaceuticals (ELDN) EBT (2013 - 2026)

Eledon Pharmaceuticals has reported EBT for 14 years, with the latest figure at -$21.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBT fell 17.91% year-over-year to -$21.2 million; the trailing twelve-month figure through Mar 2026 stood at -$82.9 million (down 468.02% YoY), and the FY2025 full-year result was -$45.6 million, down 27.49% from the prior year.
• EBT for Q1 2026 stood at -$21.2 million, down from -$19.1 million in the prior quarter.
• The five-year high for EBT was $38.4 million in Q4 2024, with the low at -$58.4 million in Q4 2022.
• Historically, EBT has averaged -$12.7 million across 5 years, with a median of -$11.2 million in 2023.
• Annual changes were most pronounced in 2022 — EBT sank 311.0% — and 2024, when it soared 368.59%.
• Eledon Pharmaceuticals' EBT stood at -$58.4 million in 2022, then surged by 114.03% to $8.2 million in 2023, then jumped by 368.59% to $38.4 million in 2024, then sank by 149.7% to -$19.1 million in 2025, then decreased by 11.07% to -$21.2 million in 2026.
• The last three EBT figures came in at -$21.2 million (Q1 2026), -$19.1 million (Q3 2025), and -$24.7 million (Q2 2025), per Business Quant data.